Logo

Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for Moderately to Severely Active Ulcerative Colitis

Share this

Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for Moderately to Severely Active Ulcerative Colitis

Shots:

  • The approval is based on P-III UNIFI studies (UNIFI-I & -M) assessing Stelara induction (6mg/kg- IV- for 8wks.) and maintenance therapy (90mg- SC- for 44wks.) vs PBO in patients with mod. to sev. UC with inadequate response to conventional therapies
  • The P-III UNIFI-I & M study results: the achievement of clinical remission (19% @ 8wks. & 45% @1yr.); @8wks. 58% of patients experience clinical response & @1yr. 43% of patients achieved clinical remission & not having steroids
  • Stelara is the first & only approved therapy for UC targeting IL-12 and IL-23 cytokines- demonstrated improvement of the colon as measured by a novel histologic-endoscopic mucosal improvement endpoint

Click here to­ read full press release/ article 

Ref: PRNewswire | Image: Janssen


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions